Biomarkers in Inflammatory Bowel Diseases
Editat de Nik Sheng Ding, Peter De Cruzen Limba Engleză Hardback – 22 mai 2019
The central structure of the book focuses on prognostic and predictive biomarkers in IBD with an emphasis on the fields of research and scientific techniques (genomics, proteomics and metabonomics) that have led to biomarker discovery and places these biomarkers within a clinical context to help understand their utility in clinical practice.
This book will be of use to clinicians who have an interest in using biomarkers in clinical practice as well as clinician researchers and scientists involved in the biomarker research pipeline.
The author team comprises experts from around the world in order to bring together the literature in an effort to inform clinicians and researchers about the current state-of-the art in biomarker discovery. It is intended to assist future research efforts and indicate how biomarkers might be best applied to clinical practice both at present and in the future.
Preț: 246.13 lei
Preț vechi: 259.09 lei
-5% Nou
Puncte Express: 369
Preț estimativ în valută:
47.10€ • 48.93$ • 39.13£
47.10€ • 48.93$ • 39.13£
Carte disponibilă
Livrare economică 11-25 ianuarie 25
Livrare express 31 decembrie 24 - 04 ianuarie 25 pentru 55.20 lei
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783030114459
ISBN-10: 3030114457
Pagini: 372
Ilustrații: XVII, 365 p. 35 illus., 30 illus. in color.
Dimensiuni: 178 x 254 x 24 mm
Greutate: 0.96 kg
Ediția:1st ed. 2019
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
ISBN-10: 3030114457
Pagini: 372
Ilustrații: XVII, 365 p. 35 illus., 30 illus. in color.
Dimensiuni: 178 x 254 x 24 mm
Greutate: 0.96 kg
Ediția:1st ed. 2019
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
Cuprins
Part I: Introduction.- nflammatory bowel disease – more than meets the eye - Clinical risk factors – lessons from epidemiology.- Clinical trial design for biomarker discovery.- Database/ big data meets real world.- Patient reported outcomes.- Part II: Biomarkers – Prognostic vs Predictive.- Biomarkers for remote monitoring.- Disease modification.- Part IIV: Crohn’s disease.- Luminal Crohn’s disease-. Perianal CD.- Fibrosis/ strictures in CD.- Post-op Crohn’s disease.- Part IV: Ulcerative colitis.- UC surveillance.- Acute severe UC.- Chronic active UC.- Pouchitis.- Refractory proctitis.- Feacal microbiota transplantation.- Primary sclerosing cholangitis.- Extraintestinal manifestations of IBD.- Part V: Specialised scenarios.- Pregnancy.- Nutrition.- TDM.- Biomarkers to quantify immune response.- Drug toxicity.- Part VI:Scientific.- Exposome and diet.- Microbiota .- Metabonomics.- Immunology.- Genomics.- Systems Biology in Biomarker research.- Part VII: Ideal tools for investigation in the future.
Notă biografică
The editors are currently reviewers of major international journals. They are experts in inflammatory bowel disease (IBD) each with an interest in developing biomarkers for research development and improving patient care. The editors have also developed strong reputations within the international IBD community and have connections with each of the nominated chapter contributors.
Nik Sheng Ding is a committee member for the European Crohn’s and Colitis Organisation (ECCO) and a clinical lecturer at Imperial College, London. He has supervised students and is a member of the Computational Medicine division of the department of medicine. He is completing a PhD entitled “Clinical and metabolic predictors of response to anti-TNF therapy in Crohn’s disease”. He has authored and co-authored manuscripts, book chapters and has a major grant from ECCO to conduct his research. He is currently the principal investigator of an international study into access to IBD investigations (biomarkers) by health professionals, particularly investigating rates of usage according to health expenditure and quality of care for patients (Access to IBD investigations – ACCID). Nik has an interest in translational research with investigating the function of the microbiome through metabonomics and it’s relation to outcomes in IBD.
Peter De Cruz MBBS, Ph.D, FRACP
Peter De Cruz is Director of the IBD service at the Austin Hospital, Senior lecturer at the University of Melbourne and Life Fellow of Clare Hall at the University of Cambridge. Peter’s doctoral research at The University of Melbourne identified the optimal strategy for preventing Crohn’s disease recurrence after resectional surgery. The findings of the research have been published in the Lancet and Gastroenterology and have changed practice internationally. His postdoctoral fellowship in complex IBD and clinical nutrition was undertaken between Addenbrooke’s Hospital, Cambridge and St Mark’s Hospital,London. Peter’s ongoing clinical research interests include identifying predictors of response to IBD therapeutics which he maintains through his translational research interest in molecular microbiology and immunology.
Nik Sheng Ding is a committee member for the European Crohn’s and Colitis Organisation (ECCO) and a clinical lecturer at Imperial College, London. He has supervised students and is a member of the Computational Medicine division of the department of medicine. He is completing a PhD entitled “Clinical and metabolic predictors of response to anti-TNF therapy in Crohn’s disease”. He has authored and co-authored manuscripts, book chapters and has a major grant from ECCO to conduct his research. He is currently the principal investigator of an international study into access to IBD investigations (biomarkers) by health professionals, particularly investigating rates of usage according to health expenditure and quality of care for patients (Access to IBD investigations – ACCID). Nik has an interest in translational research with investigating the function of the microbiome through metabonomics and it’s relation to outcomes in IBD.
Peter De Cruz MBBS, Ph.D, FRACP
Peter De Cruz is Director of the IBD service at the Austin Hospital, Senior lecturer at the University of Melbourne and Life Fellow of Clare Hall at the University of Cambridge. Peter’s doctoral research at The University of Melbourne identified the optimal strategy for preventing Crohn’s disease recurrence after resectional surgery. The findings of the research have been published in the Lancet and Gastroenterology and have changed practice internationally. His postdoctoral fellowship in complex IBD and clinical nutrition was undertaken between Addenbrooke’s Hospital, Cambridge and St Mark’s Hospital,London. Peter’s ongoing clinical research interests include identifying predictors of response to IBD therapeutics which he maintains through his translational research interest in molecular microbiology and immunology.
Textul de pe ultima copertă
This book provides a comprehensive and complete overview of biomarkers in clinical practice for inflammatory bowel disease (IBD) bringing together the literature in a clear and concise manner. The book bridges the gap between growing knowledge at the bench and current and future applications of biomarkers in clinical practice.
The central structure of the book focuses on prognostic and predictive biomarkers in IBD with an emphasis on the fields of research and scientific techniques (genomics, proteomics and metabonomics) that have led to biomarker discovery and places these biomarkers within a clinical context to help understand their utility in clinical practice.
This book will be of use to clinicians who have an interest in using biomarkers in clinical practice as well as clinician researchers and scientists involved in the biomarker research pipeline. The author team comprises experts from around the world in order to bring together the literature in an effort to inform clinicians and researchers about the current state-of-the art in biomarker discovery. It is intended to assist future research efforts and indicate how biomarkers might be best applied to clinical practice both at present and in the future
The central structure of the book focuses on prognostic and predictive biomarkers in IBD with an emphasis on the fields of research and scientific techniques (genomics, proteomics and metabonomics) that have led to biomarker discovery and places these biomarkers within a clinical context to help understand their utility in clinical practice.
This book will be of use to clinicians who have an interest in using biomarkers in clinical practice as well as clinician researchers and scientists involved in the biomarker research pipeline. The author team comprises experts from around the world in order to bring together the literature in an effort to inform clinicians and researchers about the current state-of-the art in biomarker discovery. It is intended to assist future research efforts and indicate how biomarkers might be best applied to clinical practice both at present and in the future
Caracteristici
Incorporates current biomarkers within practical algorithms that can be applied to clinical practice Addresses predictive (early or ultra early) biomarkers of response to current therapeutic agents which form the backbone of medical therapy as well as prognostic biomarkers which predict disease course in inflammatory bowel disease Presents the current state-of-the art in the research strategies that are being applied to biomarker discovery